ASH 2022: Promising Results in Newly Diagnosed and Relapsed/Refractory Multiple Myeloma

Four trials presented at ASH 2022 have shown promising results for patients with newly diagnosed or relapsed/refractory multiple myeloma.

Related Keywords

New York ,United States ,Memorial Sloan Kettering Cancer Center ,Urvia Shah , ,Mount Sinai School Of Medicine ,Talquetamab Demonstrates Activity ,Heavily Pretreated ,Ajai Chari ,Mount Sinai School ,